Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-10-05, Stock:PFE, The news for the past five days is as follows:
2018-09-28: NEWS1: Pfizer (PFE) Stock Moves 0.27%: What You Should Know.NEWS2: Pfizer (PFE) Stock Moves 0.27%: What You Should Know.NEWS3: Final Trades: T, DIS & more.NEWS4: Pfizer (PFE) Stock Moves 0.27%: What You Should Know.NEWS5: A Look at Sanofi’s Valuation Multiples in September.NEWS6: A Look at Eli Lilly’s Revenue Growth Rate.NEWS7: Pfizer's (PFE) Lung Cancer Drug Vizimpro Gets FDA Approval.NEWS8: Pfizer's (PFE) Lung Cancer Drug Vizimpro Gets FDA Approval.NEWS9: Women Health a Prime Concern Worldwide: 3 Stocks in Focus.NEWS10: Women Health a Prime Concern Worldwide: 3 Stocks in Focus.NEWS11: Pharma Stock Roundup: PFE, LLY Get Approval for New Drugs, Novartis to Cut Jobs.NEWS12: Pharma Stock Roundup: PFE, LLY Get Approval for New Drugs, Novartis to Cut Jobs.NEWS13: JNK, FTXH: Big ETF Outflows.NEWS14: JNK, FTXH: Big ETF Outflows.NEWS15: Stocks - Tesla Tumbles in Pre-market; Eli Lilly, BlackBerry Gain.NEWS16: Pfizer&apos;s (PFE) Lung Cancer Drug Vizimpro Gets FDA Approval.NEWS17: Comparing Pfizer Stock and Merck and Co. Stock.NEWS18: Pharma Stock Roundup: PFE, LLY Get Approval for New Drugs, Novartis to Cut Jobs.NEWS19: Women Health a Prime Concern Worldwide: 3 Stocks in Focus.NEWS20: Comparing Pfizer Stock and Johnson & Johnson Stock.NEWS21: The Daily Biotech Pulse: FDA Nods For Adamis, Eli Lilly, Pfizer; Spero, Obseva Report Positive Trial Results.NEWS22: Here’s What Verastem’s Valuation Trend Indicates.NEWS23: QIAGEN Receives FDA Approval To Expand Use Of EGFR Test In Lung Cancer.NEWS24: QIAGEN Receives FDA Approval To Expand Use Of EGFR Test In Lung Cancer.
2018-10-01: NEWS1: Business Highlights.NEWS2: Dow Rallies, Nasdaq Fizzles as October Kicks Off.NEWS3: Dow Rallies, Nasdaq Fizzles as October Kicks Off.NEWS4: Pfizer CEO Ian Read to Resign.NEWS5: Pfizer CEO Ian Read to Resign.NEWS6: Drugmaker Pfizer's CEO Read to be replaced by COO Bourla.NEWS7: Dow, S&P 500 End Higher on New Nafta Deal; Nasdaq Slips.NEWS8: Pfizer to replace longtime CEO Read with veteran Bourla.NEWS9: Dow, S&P 500 Hold Gains, Nasdaq Slips in Late Trading.NEWS10: Pfizer to replace longtime CEO Read with veteran Bourla.NEWS11: Pfizer's Incoming CEO Represents Pipeline Push Over Dealmaking.NEWS12: Dow Rises Sharply as U.S. and Canada Reach Trade Deal.NEWS13: Scientists behind game-changing cancer immunotherapies win Nobel medicine prize.NEWS14: Tesla Produced A Record Number of Vehicles in Q3, Report Says: LIVE MARKETS BLOG.NEWS15: Pfizer CEO Ian Read to Resign.NEWS16: Drugmaker Pfizer's CEO Read to be replaced by COO Bourla.NEWS17: Mylan Stock Declined ~12% Year-to-Date: Could It Recover Soon?.NEWS18: Saudi Arabia Shelves $200 Billion Solar Energy Project: LIVE MARKETS BLOG.NEWS19: Pfizer CEO’s Transition Leaves Wall Street Divided on M&A Strategy.NEWS20: GE’s CEO is out after only a year, and Wall Street is thrilled.NEWS21: Reviewing Pfizer’s Valuation as of September 25.NEWS22: Plurality of Economists Foresee Economic Recession by 2020: LIVE MARKETS BLOG.NEWS23: Pfizer's Next CEO May Have to Pull Off Some Bold Deals.NEWS24: Stocks Post Sharp Gains as U.S. and Canada Reach Trade Deal.NEWS25: Wall Street Expects 24% Upside Potential for MYL Stock.NEWS26: Pfizer Says CEO Ian Read to Retire; COO Albert Bourla Will Lead Group From 2019.NEWS27: Pfizer CEO Will Step Down at Year's End: LIVE MARKETS BLOG.NEWS28: Eli Lilly’s Market Cap and Shareholding Pattern.NEWS29: [$$] Stocks to Watch: GE, Tesla, Pfizer, Facebook and More.NEWS30: Comparing Pfizer Stock and Eli Lilly Stock.NEWS31: Pfizer CEO set to resign, replacement named.NEWS32: Apple Was The Top Dow Jones Stock In Q3, But This Winner May Surprise You.NEWS33: [$$] Revamped Nafta deal gives S&P 500 shot at record high.NEWS34: Pfizer says CEO Ian Read will retire at the end of the year.NEWS35: Pfizer’s Dividend Growth Trend and Analysts’ Recommendations.NEWS36: Comparing Pfizer Stock and Bristol-Myers Squibb Stock.NEWS37: [$$] Ian Read to step aside as Pfizer chief executive.NEWS38: Pfizer CEO to step down.NEWS39: Pfizer announces Dr. Albert Bourla will succeed CEO Ian Read effective January 1.NEWS40: Pfizer Announces CEO Succession.NEWS41: Pfizer: Albert Bourla To Succeed Ian Read As CEO Effective Jan. 1.NEWS42: Pfizer: Albert Bourla To Succeed Ian Read As CEO Effective Jan. 1.NEWS43: [$$] Let’s Throw a Patent-Burning Party.
2018-10-02: NEWS1: Is Pfizer (PFE) Stock Outpacing Its Medical Peers This Year?.NEWS2: Is Pfizer (PFE) Stock Outpacing Its Medical Peers This Year?.NEWS3: Pfizer's CEO Ian Read to Step Down Next Year, COO to Succeed.NEWS4: Pfizer's CEO Ian Read to Step Down Next Year, COO to Succeed.NEWS5: QIAGEN's FDA Nod for Expanded EGFR Test Use Widens Suite.NEWS6: QIAGEN's FDA Nod for Expanded EGFR Test Use Widens Suite.NEWS7: Why Pfizer (PFE) is a Great Dividend Stock Right Now.NEWS8: Why Pfizer (PFE) is a Great Dividend Stock Right Now.NEWS9: Examining the Performances of Eli Lilly’s Oncology Products.NEWS10: Pfizer&apos;s CEO Ian Read to Step Down Next Year, COO to Succeed.NEWS11: Is Pfizer (PFE) Stock Outpacing Its Medical Peers This Year?.NEWS12: Why Pfizer (PFE) is a Great Dividend Stock Right Now.NEWS13: QIAGEN&apos;s FDA Nod for Expanded EGFR Test Use Widens Suite.NEWS14: A Look at GlaxoSmithKline’s Consumer Healthcare Business.NEWS15: Does Mylan’s Low Valuation Provide a ‘Buy’ Opportunity?.NEWS16: A Closer Look at Eli Lilly’s Human Pharmaceutical Business.NEWS17: [$$] Since 2000 GE has paid $6bn in adviser fees. Was it worth it?.NEWS18: [$$] Pfizer: pill will.NEWS19: [$$] EpiPen dearth shows company and regulator failure.NEWS20: [$$] Pfizer Counts on Pipeline to Bring Growth.NEWS21: [$$] Pfizer CEO Read to Step Aside at Year’s End.NEWS22: PRESS DIGEST- British Business - Oct 2.
2018-10-03: NEWS1: Merck CEO sees a disintermediation in pharma like the cable industry.NEWS2: How Did Pharmaceutical ETFs Perform in Q3 2018?.NEWS3: Novartis, Boston Pharma Ink Deal for 3 Anti-Infective Drugs.NEWS4: Novartis, Boston Pharma Ink Deal for 3 Anti-Infective Drugs.NEWS5: Notable ETF Inflow Detected - SPYG, ABT, INTC, PFE.NEWS6: Notable ETF Inflow Detected - SPYG, ABT, INTC, PFE.NEWS7: A Look at Elanco, Eli Lilly’s Animal Health Business.NEWS8: Novartis, Boston Pharma Ink Deal for 3 Anti-Infective Drugs.NEWS9: Health Care Sector Update for 10/03/2018: JNJ, PFE, AMGN, MRK, ABT, ELGX, NVCN, KALA.NEWS10: Health Care Sector Update for 10/03/2018: JNJ, PFE, AMGN, MRK, ABT, ELGX, NVCN, KALA.NEWS11: Bristol-Myers Squibb Company (BMY) Ex-Dividend Date Scheduled for October 04, 2018.NEWS12: Bristol-Myers Squibb Company (BMY) Ex-Dividend Date Scheduled for October 04, 2018.NEWS13: How Have Eli Lilly’s Endocrine Products Been Performing?.NEWS14: [$$] Lex letter from New York: chiefs checked.NEWS15: Wide Moat Surrounds Pfizer's Solid Foundation.NEWS16: The 5 Best Dow Jones Stocks to Buy Now.NEWS17: The 5 Best Dow Jones Stocks to Buy Now.NEWS18: With Hemlibra, Roche seeks to break into tight hemophilia circle.
2018-10-04: NEWS1: Top Performing ETFs of the Third Quarter.NEWS2: Top Performing ETFs of the Third Quarter.NEWS3: What AbbVie’s Valuation Trend Indicates.NEWS4: Seattle Genetics: Impact of the Cascadian Acquisition.NEWS5: Antares Pharma Is Expected to Report Positive EPS in 2019.NEWS6: 5 Reasons Why Investors Should Bet on Pfizer (PFE) Stock.NEWS7: 5 Reasons Why Investors Should Bet on Pfizer (PFE) Stock.NEWS8: J&J's Phase III Data Shows Switch to its HIV Drug Beneficial.NEWS9: J&J's Phase III Data Shows Switch to its HIV Drug Beneficial.NEWS10: Amgen’s Stock Performance and Estimates after Q3 2018.NEWS11: 5 Reasons Why Investors Should Bet on Pfizer (PFE) Stock.NEWS12: Better Buy: Gilead Sciences, Inc. vs. Pfizer.NEWS13: Better Buy: Gilead Sciences, Inc. vs. Pfizer.NEWS14: Better Buy: Gilead Sciences, Inc. vs. Pfizer.NEWS15: How Did Pfizer Stock Fare in Q3 2018?.NEWS16: Eli Lilly’s Stock Performance and Estimates for Q3 2018.NEWS17: Moody's: Biosimilars a growing challenge biotech drugs, with European market developing more quickly than the US.

Answer: Rise